Navigation Links
New Clinical Study Finds that Nutraceutical Deepak Chopra Endorphinate® Provides Effective, Safe Relief for Chronic Anxiety, Depression, Cravings & Pain Hypersensitivity
Date:9/27/2013

Carlsbad, California (PRWEB) September 27, 2013

Groundbreaking research published this week in the Journal of Behavioral and Brain Science* (JBBS) shows that the nutraceutical Endorphinate® is a clinically effective and safe treatment for chronic emotional and physical distress, including anxiety, anger, depression, cravings, and pain hypersensitivity.

Developed by a team of scientists associated with mind-body healing pioneer and endocrinologist Deepak Chopra, M.D., and world-renowned neurologist and Alzheimer’s researcher Dr. Rudolph Tanzi, Endorphinate is a scientific formulation of health-promoting plant extracts and amino acids that is produced and distributed worldwide by Pondera Pharmaceuticals, Inc. Endorphinate® has a direct effect on endorphins, which are natural brain chemicals that create a sense of calm, pleasure, and wellbeing. Endorphinate® combines specific agents that increase the release of endorphins with agents that switch endorphin receptors from an excitatory (distress/pain) to an inhibitory (calm/comfort) mode.

As the peer-reviewed study published in JBBS describes, a team of scientists led by Dr. Stanley M. Crain, Professor Emeritus, Dept. of Neuroscience, Albert Einstein College of Medicine, and Dr. Steven Crain, neuropsychotherapist carried out a 26-month study to assess the benefits of Endorphinate® for individuals suffering from moderate-to-severe emotional and/or physical distress. Through direct treatment and close clinical supervision by Dr. Steven Crain, researchers conducted 203 clinical case studies of both females and males ranging in age from 14 to 85.

The study found that Endorphinate® provided strong clinical benefits, including reduced anxiety, anger, depressed mood, pain hypersensitivity, and cravings. Most participants reported greater calm, comfort, well-being, and pleasure as well as increased mental clarity, energy, productivity, healthier lifestyle choices, and an adaptive response to life’s stresses.

“It’s wonderful to have scientific data supporting the benefits of a natural, non-prescription supplement like Endorphinate®,” said Deepak Chopra. “I have been taking Endorphinate® every day for over a year and have been experiencing its beneficial effects. It has become the number one dietary supplement used by our clients and patients at the Chopra Center. I unhesitatingly endorse and support the use of Endorphinate® to help increase resistance to stress, anxiety, trauma, cravings, and fatigue."

*Steven Crain, Matthew A. Crain, and Stanley M. Crain, “Emotional and Physical
Distress Relief Using a Novel Endorphinergic Formulation,” Journal of Behavioral and Brain Science, Vol. 3, Issue 6, 2013, pp. 441-453. (Link to Article)

For press inquiries and interviews about the science of endorphins and the new study of Endorphinate published in the Journal of Behavioral and Brain Science, contact:

Steven Crain, Ph.D.
Neuropsychotherapist, Therapeutic Alliance
Clinical Director, Pondera Pharmaceuticals Inc.
315 S. Allen St., Suite 422
State College, PA 16801
814-769-1980
DrStevenCrain(at)aol(dot)com

For press inquiries about Deepak Chopra and the Chopra Center for Wellbeing, please contact:

Kathy Bankerd
Chopra Center Marketing Director
(760) 494-1609
http://www.chopra.com

About Deepak Chopra, M.D., F.A.C.P.
Founder of the Chopra Center for Wellbeing
Deepak Chopra, M.D. is the author of more than 65 books, including numerous New York Times bestsellers. His medical training is in internal medicine and endocrinology, and he is a Fellow of the American College of Physicians, a member of the American Association of Clinical Endocrinologists, and an adjunct professor of Executive Programs at the Kellogg School of Management at Northwestern University. He is also a Distinguished Executive Scholar at Columbia Business School, Columbia University, and a Senior Scientist at the Gallup organization. For more than a decade, he has participated as a lecturer at the Update in Internal Medicine, an annual event sponsored by Harvard Medical School’s Department of Continuing Education and the Department of Medicine, Beth Israel Deaconess Medical Center.

###

Read the full story at http://www.prweb.com/releases/2013/9/prweb11168691.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. Clinical insight improves treatment with new lung cancer drug
3. Clinical news alert from the American Academy of Orthopaedic Surgeons
4. NYU Langone experts present research, clinical advances at neurosurgeons meeting
5. Kroenke honored for outstanding contributions in clinical research training
6. Awards celebrate clinical research that can improve health and alleviate suffering
7. Association for Psychological Science, SAGE launch Clinical Psychological Science
8. URMC clinical trial tests new regimen for hypertension
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: